Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
PTC Therapeutics, Inc.
ISIN US69366J2006
|WKN A1W0MW
Market cap (in EUR)
5,298 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Advertisement
Capital at risk. Execution-only service.
Overview
Description
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 5,298 m |
| EPS, EUR | 7.75 |
| P/B ratio | - |
| P/E ratio | 9.1 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 746 m |
| Net income, EUR | -336 m |
| Profit margin | -45.03% |
What ETF is PTC Therapeutics, Inc. in?
There are 31 ETFs which contain PTC Therapeutics, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of PTC Therapeutics, Inc. is the L&G Pharma Breakthrough UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.